Century Pharma Ltd., a reputed API Manufacturing Company in India, is committed to delivering premium-quality Active Pharmaceutical Ingredients to global pharmaceutical leaders. Among our specialised offerings, Bimatoprost stands out as a highly effective ophthalmic solution, widely used for the treatment of open-angle glaucoma and ocular hypertension. With a strong emphasis on safety, stability, and purity, we ensure that every batch of Bimatoprost API meets stringent international standards, supporting our partners in producing life-enhancing eye care medications.
Recognised as one of the most reliable Bimatoprost API Manufacturers in India, we operate from our state-of-the-art manufacturing facility located in Vadodara, Gujarat. Our team of experienced scientists and regulatory experts ensures that the production of Bimatoprost API is compliant with global pharmacopoeial requirements, including USFDA and EU guidelines. As one of the most trusted Bimatoprost API Manufacturers in Vadodara, Gujarat, we are dedicated to maintaining product integrity through rigorous quality assurance and control processes.
Century Pharma Ltd. also offers flexible and reliable supply solutions as a Bimatoprost API Trader in India. With a wide distribution network and strong logistics support, we cater to the varied procurement needs of pharmaceutical companies across the country. Whether you are seeking a reliable Bimatoprost API Trader in Gujarat or a dependable partner in Vadodara, our team ensures timely delivery and competitive pricing to keep your production timelines on track.
Driven by innovation and customer-centricity, Century Pharma, an excellent Bimatoprost API Trader in Vadodara, goes beyond API supply by offering long-term partnerships for the development of new APIs and the manufacturing of key intermediates. As one of the leading Bimatoprost API Manufacturers in Gujarat, we are committed to delivering excellence through precision, compliance, and trust, helping our global clients achieve sustainable growth and product innovation in the ophthalmic care segment.
Century Pharma has established a robust global presence, delivering high-quality Active Pharmaceutical Ingredients (APIs) and services across key international markets. With strong footprints in Egypt, Vietnam, Mexico, Russia, Korea, and several MENA/GCC countries (Algeria, Bahrain, Djibouti, Egypt, Iran, Iraq, Jordan, Kuwait, Lebanon, Libya, Mauritania, Morocco, Oman, Qatar, Saudi Arabia, Somalia, Sudan, Syria, Tunisia, the United Arab Emirates, and Yemen.), Century Pharma supports pharmaceutical advancements worldwide. Our expertise spans API manufacturing for human and animal health, enzyme production, biotechnology, and API research.
Additionally, Century Pharma excels in Contract API Manufacturing, Contract API Research, Method API Development, and Stability Studies, catering to regulatory and market-specific needs. As a trusted API manufacturer in India, Century Pharma continues to expand its global reach, fostering long-term collaborations and ensuring quality healthcare solutions across continents.
Century Pharma Ltd. is a Bimatoprost API manufacturer based in Vadodara, Gujarat, India. We support pharmaceutical companies with API sourcing and commercial enquiries. Contact our team to discuss your required quantity, product specifications, and delivery destination.
Pharmaceutical buyers can enquire about the applicable Certificate of Analysis (COA) and product specifications. These documents help buyers assess API identity, purity, and batch quality. Contact Century Pharma to confirm documentation availability.
The minimum order quantity depends on product availability, purchase volume, and commercial requirements. Buyers can share their expected quantity with Century Pharma to confirm MOQ, pricing, and delivery schedules.
Century Pharma serves international pharmaceutical markets. Buyers can enquire about Bimatoprost API availability, export documentation, and shipping arrangements for their destination country. Supply is subject to applicable regulatory requirements.
To request a quotation, share your required quantity, product grade, quality specifications, destination country, and delivery schedule. Century Pharma can review your requirements and provide available commercial details.
Buyers should review assay, identification, related substances, residual solvents, and applicable quality specifications. They should also evaluate the impurity profile, stereochemical identity, stability data, and batch test results. These checks help pharmaceutical manufacturers assess product quality.
Manufacturers should evaluate API purity, degradation impurities, solubility, stability, and compatibility with their intended ophthalmic formulation. They should also confirm the applicable microbial and endotoxin requirements. Finished ophthalmic products must meet the relevant sterility and quality standards.
Not necessarily. Bimatoprost API intended for ophthalmic formulation is not automatically sterile. Pharmaceutical buyers should confirm the supplied material’s microbial specifications, manufacturing controls, and any applicable endotoxin requirements. They should also assess the intended sterilisation process and finished-product requirements.
Stability and impurity controls help pharmaceutical manufacturers evaluate API quality throughout storage and formulation development. Buyers should review relevant degradation products, stability data, recommended storage conditions, and protective packaging. Contact Century Pharma to enquire about available technical documentation.
Bimatoprost is a synthetic prostamide analogue, while Latanoprost is a prostaglandin F2α analogue supplied as an isopropyl ester. Both are used in approved ophthalmic products to reduce elevated intraocular pressure. However, they differ in chemical structure and formulation characteristics. Manufacturers should select the API specified in their approved product and regulatory documents.
Pharmaceutical buyers should request applicable product specifications, batch COA, GMP evidence, stability data, and available regulatory support documents. They should also review impurity controls and relevant microbiological requirements. Documentation requirements depend on the destination market and intended ophthalmic formulation.